Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Marketing Surveillance (Usage Results Study) of Brigatinib in the Treatment of Adult Patients for Approved Indications in South Korea

NCT04592523 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT04592523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04592523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Marketing Surveillance (Usage Results Study) of Brigatinib in the Treatment of Adult Patients for Approved Indications in South Korea
Lead sponsor
Takeda
Phase
Observational
Overall status
Completed
Start date
September 5, 2019
Completion date
March 12, 2026
Enrollment
271 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic lymphoma kinase, carcinoma, non-small-cell lung